Renaissance Technologies’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-164,100
| Closed | -$740K | – | 4006 |
|
|
2025
Q2 | $740K | Sell |
164,100
-92,606
| -36% | -$416K | ﹤0.01% | 2648 |
|
|
2025
Q1 | $1.14M | Buy |
256,706
+125,106
| +95% | +$726K | ﹤0.01% | 2337 |
|
|
2024
Q4 | $1.03M | Buy |
131,600
+103,700
| +372% | +$1.26M | ﹤0.01% | 2486 |
|
|
2024
Q3 | $367K | Sell |
27,900
-36,737
| -57% | -$466K | ﹤0.01% | 2905 |
|
|
2024
Q2 | $781K | Sell |
64,637
-50,663
| -44% | -$684K | ﹤0.01% | 2461 |
|
|
2024
Q1 | $1.88M | Sell |
115,300
-59,500
| -34% | -$802K | ﹤0.01% | 2075 |
|
|
2023
Q4 | $1.19M | Sell |
174,800
-62,290
| -26% | -$360K | ﹤0.01% | 2287 |
|
|
2023
Q3 | $1.29M | Buy |
237,090
+20,890
| +10% | +$122K | ﹤0.01% | 2130 |
|
|
2023
Q2 | $1.47M | Buy |
216,200
+128,800
| +147% | +$965K | ﹤0.01% | 2202 |
|
|
2023
Q1 | $438K | Buy |
87,400
+33,900
| +63% | +$138K | ﹤0.01% | 2951 |
|
|
2022
Q4 | $261K | Sell |
53,500
-74,400
| -58% | -$541K | ﹤0.01% | 3293 |
|
|
2022
Q3 | $1.84M | Sell |
127,900
-21,900
| -15% | -$363K | ﹤0.01% | 2063 |
|
|
2022
Q2 | $2.27M | Buy |
149,800
+58,800
| +65% | +$686K | ﹤0.01% | 2100 |
|
|
2022
Q1 | $1.08M | Sell |
91,000
-7,600
| -8% | -$78K | ﹤0.01% | 2678 |
|
|
2021
Q4 | $1.6M | Buy |
+98,600
| New | +$2.11M | ﹤0.01% | 2323 |
|
|
2021
Q2 | – | Sell |
-32,200
| Closed | -$974K | – | 3822 |
|
|
2021
Q1 | $974K | Buy |
+32,200
| New | +$1.32M | ﹤0.01% | 2620 |
|
|
2020
Q1 | – | Sell |
-26,000
| Closed | -$813K | – | 3869 |
|
|
2019
Q4 | $813K | Sell |
26,000
-44,700
| -63% | -$1.32M | ﹤0.01% | 2721 |
|
|
2019
Q3 | $1.84M | Buy |
70,700
+28,900
| +69% | +$738K | ﹤0.01% | 2323 |
|
|
2019
Q2 | $956K | Buy |
+41,800
| New | +$960K | ﹤0.01% | 2701 |
|
Other funds holding YMAB
Renaissance Technologies's YMAB Position: Q3 2025 in Review
Renaissance Technologies sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 164,100 shares — an estimated $740K sold.
Renaissance Technologies first reported a position in YMAB in Q2 2019 and held it in 19 quarters. The position peaked at $2.27M in Q2 2022. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Renaissance Technologies reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Renaissance Technologies sold 164,100 Y-mAbs Therapeutics shares in Q3 2025, an estimated $740K.
- Renaissance Technologies first reported a position in Y-mAbs Therapeutics in Q2 2019 and held it in 19 quarters.
- Renaissance Technologies's Y-mAbs Therapeutics position peaked at $2.27M in Q2 2022.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Renaissance Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.